DERMCARE BARAZONE 0.25 g/L BUDESONIDE LEAVE-ON CONDITIONER

Land: Ástralía

Tungumál: enska

Heimild: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Virkt innihaldsefni:

BUDESONIDE

Fáanlegur frá:

DERMCARE-VET PTY. LTD.

Lyfjaform:

TOPICAL CREAM, OINTMENT, PASTE, GEL, LOTION

Samsetning:

BUDESONIDE Active 0.25 g/L

Einingar í pakka:

100 mL

Tegund:

VM - Veterinary Medicine

Lækningarsvæði:

ENDOCRINE SYSTEM

Vörulýsing:

Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [CANINE ATOPIC DERMATITIS, CONTACT ALLERGY, PRURITIC CONDITIONS]

Leyfisstaða:

Registered

Leyfisdagur:

2021-07-01

Upplýsingar fylgiseðill

DERMCARE BARAZONE 0.25 g/L BUDESONIDE LEAVE-ON CONDITIONER
82108/136828
Product Name:
APVMA Approval No:
Label Name:
DERMCARE BARAZONE 0.25 g/L BUDESONIDE LEAVE-ON CONDITIONER
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
READ SAFETY DIRECTIONS BEFORE OPENING OR USING
Constituent
Statements:
0.25 g/L BUDESONIDE
Claims:
For use only by or under supervision of a veterinarian.
For the symptomatic treatment of Canine Atopic Dermatitis, contact
allergy and other
pruritic conditions of the dog.
Net Contents:
100 mL
Directions for Use:
Restraints:
Contraindications:
NOT TO BE USED in any situation where corticosteroids are
contraindicated.
Precautions:
Use with caution. Dermcare Barazone Budesonide Leave-On Conditioner
contains an
anti-inflammatory corticosteroid (budesonide). Side effects are
consistent with the use of
corticosteroids. The use of Barazone in conjunction with other topical
glucocorticoids or
systemic glucocorticoids has not been established. Concurrent use of
these medications
may increase the risk of side effects associated with corticosteroids.
Barazone may affect the results of an Intradermal Skin Test or biopsy.
The use of this product has not been tested in stud dogs and pregnant
or lactating bitches.
Its use in these animals should be based on a risk-benefit analysis by
the prescribing
veterinarian. RLP APPROVED
Long term application of this product should be done so with caution.
Monitoring of side
effects associated with the use of topical glucocorticoids should be
carried out by a
registered veterinarian.
Potential adverse reactions of topical glucocorticoids include coat
thinning, slow regrowth
of hair, atrophy of the skin, and erythema. In the Target Animal
Safety Studies conducted,
there were no serious adverse events reported. No reports of clinical
changes to the coat
or skin occurred when up to 3x maximum dose rate was applied for 6
consecutive weeks.
Routine haematology and biochemistry parameters remained within
reference ranges afte